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Abstract Nef gene function is diverse among virus isolates of
primate immunodeficiency viruses. We found differential effects
of nef mutation on the virus replication between two HIV-1
clones, NL432 and LAI. The nef mutation in NL432 affected the
infectivity more severely compared with that in LAI, although the
Nef functions of both clones were comparable. Analysis with a
series of chimeric viruses between NL432 and LAI revealed that
the gag-pol region was responsible for the differential effect of
nef mutation. The functional association between Nef and gag-
pol suggested that one of the potential targets of Nef was located
within the gag-pol region.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
In addition to the prototypic retroviral gag, pol, and env
genes, lentiviruses encode a number of accessory genes that
are unique to primate immunode¢ciency viruses. The nef gene
is one of the accessory genes and its function is essential for
the maintenance of high levels of viral replication and patho-
genesis in adult macaques infected with simian immunode¢-
ciency virus [1]. The contribution of Nef to viral replication
and pathogenesis has been highlighted by recent ¢ndings
showing that human immunode¢ciency virus (HIV) isolates
from some long-term non-progressors have deletions in the
nef gene [2].
Unlike the in vivo results, the function of Nef in vitro had
been unclear. The in vitro analysis is perplexed by the fact
that the e¡ect of Nef on viral infectivity is varied among the
isolates and is dependent upon cell type [3,4]. However, evi-
dence is accumulating that Nef enhances viral infectivity in
vitro. The upregulation of viral replication by Nef has been
reported to be mediated through an increase in proviral DNA
synthesis [5,6], but the mechanism remains unknown for the
most part. Among the known activities of Nef, its association
with cellular kinases is likely to be involved in the enhance-
ment of viral infectivity. Nef has been reported to interfere
with the function of the Src family kinases, Lck and Hck,
through the interaction between a Src homology 3 domain
of each kinase and a highly conserved polyproline type II
helix-structured proline motif within Nef, the disruption of
which a¡ects HIV replication [7,8].
The diversity of Nef function among HIV-1 isolates might
re£ect the di¡erent pathogenicity of the virus in vivo. It is,
therefore, worth analyzing the mechanism(s) for the diversity
to clarify the molecular function of Nef. In this study, we
found diverse e¡ects of nef mutation on viral replication in
two HIV-1 clones, NL432 and LAI, and show a functional
association between Nef and the gag-pol region.
2. Materials and methods
2.1. Cell culture and transfection
HeLa cells and SW480 cells were maintained in Dulbecco’s modi-
¢ed Eagle’s medium (D-MEM) containing 10% heat-inactivated fetal
bovine serum (FBS). The CD4 human leukemia cell line A3.01 [9]
was maintained in RPMI 1640 medium containing 10% FBS. HeLa-
CD4 cells were maintained in D-MEM supplemented with 10% FBS,
and 0.2 mg/ml Geneticin (G418; Gibco/BRL). HeLa-CD4-LTR-L-gal
cells (MAGI cells; multinuclear activation of a galactosidase indica-
tor) [10] were propagated in D-MEM supplemented with 10% FBS,
0.2 mg/ml Geneticin, and 0.1 mg/ml hygromycin B (Sigma). For trans-
fection, the calcium phosphate co-precipitation [11] and the modi¢ed
DEAE-dextran methods [12] were used for adherent and suspension
cells, respectively.
2.2. Provirus DNA constructs
An infectious proviral clone of HIV-1, pNL432 (GenBank accession
number G328415) and its nef mutant, pNL432-vnef, have been de-
scribed (previously designated pNL-Xh) [13]. The pLAI nef mutant
clone, pLAI-vnef, was constructed from pLAI (GenBank accession
number K02013, kindly provided by Dr. Keith Peden) by inserting
the stop codon linker into the XhoI site found in the nef open reading
frame. The chimeric virus clones, pLain DNAs, were constructed by a
standard DNA manipulation (Figs. 1A and 3). The pLain-vrev-Luc
series shown in Fig. 3 were constructed from pLain series which have
a point mutation at the rev ATG initiation codon (ATG is substituted
with ATC) and an insertion of the luciferase coding gene (derived
from pGL3-basic, Clontech) in the nef region (XhoI site).
2.3. Analysis of virus growth kinetics
The viral stocks used for the infection were prepared from HeLa
cells transfected with infectious molecular clones. A3.01 cells (1U106
cells) were infected for 6 h with the virus stock in 1 ml of growth
medium in the presence of 2 Wg/ml polybrene. The amounts of input
virus were adjusted according to the amount of p24 (30 ng of p24,
which was determined by HIV-1 p24 antigen ELISA; Cellular Prod-
ucts). Fresh growth medium (4 ml) was added to the infected cells
after the incubation. Every 2 days after infection, the culture super-
natant was harvested and the RT activity was monitored by a stand-
ard method [14]. The RT activity was determined as the photo-stimu-
lated luminescence (PSL) with a BAS-2000 image analyzer (Fuji
Film).
2.4. MAGI assay
The viral stocks were obtained from the HeLa or SW480 cells trans-
fected with DNA clones. The viruses from infected A3.01 cells were
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also used as viral stock. MAGI cells were infected with the same
amount of virus (adjusted with the RT activity) in the presence of
2 Wg/ml polybrene, and the L-galactosidase activity in the cells was
monitored at 20 h after infection by the Luminescent L-galactosidase
Genetic Reporter System II (Clontech).
2.5. Expression vectors
The Nef-GFP fusion genes were obtained by inserting the nef genes
of NL432 and LAI into pEGFP-1 plasmid (Clontech), then the fusion
genes were subcloned into the pCMV4 mammalian expression vector
[15]. The obtained expression plasmids were designated pNL-Nef-
GFP and pLAI-Nef-GFP. The rev expression plasmid, pCMV-F-
Rev, was obtained by inserting the rev gene into pCMV4. The rev
gene was derived from the rev expression plasmid, pCV-1, which
has been described previously [16].
2.6. Single-round infection
pLain-vrev-Luc, pCMV-F-Rev, and pNL-Nef-GFP were used for
single-round infection assay. pLain-vrev-Luc was transfected into
HeLa cells, and Rev and Nef-GFP proteins were supplied from the
expression plasmids in trans. CD4-HeLa cells were infected with an
equal amount of virus. Three days after infection, the luciferase ac-
tivity in the cells was assayed with the Luciferase Assay System
(Promega).
2.7. Assays of viral entry
Viral stocks were obtained as the supernatants of HeLa cells trans-
fected with DNA clones. MAGI cells (1U106) were incubated with
the viruses for 4 h at 37‡C in the presence of 2 Wg/ml polybrene. At 4 h
after infection, the cells were washed, trypsinized, and resuspended in
FBS. One part containing 1/10 of the total number of cells was lysed
in phosphate-bu¡ered saline containing 1% Triton X-100 and ana-
lyzed by p24 antigen ELISA to quantify intracellular CA protein
[17]. The other portion was placed back in culture medium at 37‡C
and cultured for an additional 14 h, then subjected to MAGI assay.
3. Results
3.1. Di¡erential e¡ect of nef mutation on the infectivity of
NL432 and LAI
The e¡ect of nef mutation on the virus replication was
reported to be dependent on the virus strain [3]. We compared
the growth kinetics of wild type (WT) and nef mutant viruses
derived from NL432 and LAI in A3.01 cells (Fig. 1B). These
two viruses are T-cell line tropic and closely related to each
other. In the case of the NL432 clone, the growth kinetics of
nef mutant (vnef) was apparently retarded in comparison with
that of WT. However, the nef mutation in LAI had only a
slight e¡ect on virus replication, indicating that the require-
ment of Nef function for the virus replication was di¡erent
between these HIV-1 clones. A similar result was obtained
with another T-cell line, H9 (data not shown).
3.2. Nef function is comparable between NL432 and LAI
viruses
The amino acid homology between Nefs of NL432 and LAI
is 98.1% as calculated by analyzing software (GENETIX-
Fig. 1. Functional diversity of Nef function between NL432 and LAI viruses. A: Genomic structures of NL432, LAI, and the chimeric viruses,
Lain1 and Lain3. B: Growth kinetics of WT and vnef viruses. A3.01 cells were infected with NL432, LAI, Lain1 or Lain3. On the day after
infection indicated in the ¢gure, the RT activity in the culture supernatant was monitored. The RT activity is indicated as PSL units.
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Mac, Software Development Co., Ltd.), which indicates that
these Nefs are closely related to each other. It was possible,
however, that the di¡erential e¡ect of the nef mutation was
determined by the diversity of the nef gene. A comparison of
amino acid sequences revealed four substitutions between
these Nefs, which are located outside the functional domains
reported previously [1]. To test whether or not these substitu-
tions conferred the di¡erence of Nef function, the infectivity
of nef-de¢cient NL432 virus (NL432-vnef) complemented
with Nef in trans was analyzed using MAGI reporter cells
(Fig. 2). Nefs derived from NL432 and LAI were expressed
as GFP fusion proteins. The Nef-GFP protein in the trans-
fected cells was easily detectable and primarily localized in
plasma membrane as reported previously (data not shown)
[18]. The mutation of the nef gene reduced the infectivity of
NL432 severely (about 15% infectivity of WT). In the com-
plementation experiment, NL-Nef-GFP and LAI-Nef-GFP
enhanced the infectivity of NL432-vnef to the same extent,
indicating that there was no functional di¡erence between
these Nefs as to the enhancement e¡ect on infectivity. Similar
results were obtained with the viral stocks derived from either
SW480 or A3.01 cells. The infectivities of Nef complemented
viruses were lower than that of WT virus, suggesting the ex-
pression level of Nef was not optimal for the enhancement of
viral infectivity. It was also possible that the e¡ect of multi-
round infection augmented the di¡erence, because Nef com-
plementation had an e¡ect only on the ¢rst round of infection.
3.3. Detailed mapping of the determinant for the Nef
mutational e¡ect
The result described above indicated that the di¡erent e¡ect
Fig. 2. Functional assay of the Nef activity on enhancement of viral
infectivity. Viruses were produced from HeLa cells by cotransfection
of pNL432-vnef and Nef expression plasmid (pNL-Nef-GFP or
pLAI-Nef-GFP), and their infectivities were assayed using MAGI
cells as described in Fig. 1. The result represents the average of
three independent experiments, and the standard deviations are indi-
cated as error bars. The L-galactosidase activities in the cells in-
fected with WT viruses (NL432) and in the mock-infected cells
(mock) are indicated as 100% and 0%, respectively.
Fig. 3. Detailed mapping of the determinant for the Nef mutational e¡ect by a single-round assay. Genomic organizations of chimeric viruses
are depicted in the ¢gure (closed and open bars indicate the sequences derived from NL432 and LAI, respectively). The origin of env is indi-
cated separately. pLain-vrev-Luc and pCMV-F-Rev and/or pNL-Nef-GFP were co-transfected into HeLa cells and the obtained viruses were
used for single-round infection assay. CD4-HeLa cells were infected with the same amount of virus (adjusted with RT activity), and the lucifer-
ase activity in the cells was monitored at 40 h after infection by a standard assay. Data were obtained from ¢ve independent experiments, and
the standard deviations are indicated as error bars. The luciferase activities are shown as relative luciferase activity (RLU) and the fold activa-
tion of virion infectivity by nef is indicated.
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of nef mutation in NL432 and LAI was determined by re-
gion(s) other than the nef gene. To identify the determinant,
two chimeric clones (Lain1 and Lain3) were constructed and
their growth abilities in A3.01 were analyzed. The 3P portions
of Lain1 and Lain3 were both derived from NL432 (Fig. 1A;
SalI-BamHI). As shown in Fig. 1B, Lain1 and Lain3 exhibited
NL432-type and LAI-type phenotypes for nef mutation, re-
spectively, suggesting the determinant for the di¡erent e¡ect
of nef mutation was located in the 5P region (BssHII-SalI)
encompassing the gag-pol, vif and 5P portion of vpr.
To map the determinant(s) for the nef mutation in detail,
additional chimeric viruses (Lain series) were constructed
as depicted in Fig. 3. The e¡ect of nef mutation in these
chimeric viruses was monitored by a modi¢ed single-round
infection assay. Virus stocks were obtained from the cells
transfected with pLain-vrev-Luc, pCMV-F-Rev and pNL-
Nef-GFP. The virus produced from the transfected cells con-
tained a mutation in rev ; thus it was defective for virion
production, making it possible to analyze the progress of
the early phase of infection by monitoring the luciferase
activity without the e¡ect of multi-round infection. The
result clearly indicated that the nef mutation a¡ected the early
phase of infection and that the ApaI-Bst1107I portion in the
gag-pol region conferred the di¡erential e¡ect of nef mutation
observed between NL432 and LAI. By comparing the infec-
tivities of Lain-vrev-Luc viruses, it was revealed that the in-
fectivities of nef-de¢cient viruses were almost the same but
those having the NL432-derived sequence encompassing
ApaI-Bst1107I (NL432 and Lain1, 4, 5, 9, and 12) were
much enhanced by Nef complementation, suggesting the aug-
mentation of viral infectivity by Nef was determined by this
region.
We also analyzed the growth kinetics of replication-compe-
tent Lain viruses in A3.01 cells and some of the results are
shown in Fig. 4. The minimal region for the NL-like pheno-
type for nef mutation could be mapped within the ApaI-
Bst1107I in gag-pol region, supporting the result obtained
with single-round infection assay.
Fig. 4. Growth capabilities of the chimeric viruses. Replication-competent Lain viruses which are similar to those shown in Fig. 3 but have in-
tact rev were used for the infection assay. The virus stocks used for the infection were prepared from HeLa cells transfected with plasmid
DNA clones. The RT activity post infection was monitored by a standard assay, which is indicated as PSL units.
Table 1
Relative RT activitya (103) Entryb (ng/106 cells) Infectivityc
RLU Fold activationd
Mock 0 0 0 ^
NL432 12.09 10.0 261 000 U7.4
NL432-vnef 10.77 11.2 35 326
LAI 12.88 9.7 169 965 U3.8
LAI-vnef 11.33 10.1 44 765
Lain3 15.47 10.5 170 329 U4.6
Lain3-vnef 13.37 10.3 37 343
Lain5 16.17 8.3 272 131 U8.4
Lain5-vnef 16.64 9.1 32 417
Lain9 13.36 8.5 260 878 U7.1
Lain9-vnef 14.05 9.0 36 522
Lain10 15.98 7.6 159 699 U4.5
Lain10-vnef 15.79 8.0 35 454
aRT activity (PSL unit) of culture supernatant of the transfected HeLa cells.
bVirus entry was quanti¢ed at 4 h after infection by measuring the intracellular HIV-1 p24 protein concentration of the MAGI cells infected
with equal amount of viral stock. The results represent nanograms of p24 antigen per 106 cells.
cViral infectivity was measured by the luminescent MAGI assay and the results are shown as relative luminescent units (RLU).
dEnhancement of viral infectivity by Nef function is indicated.
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3.4. E¡ect of nef mutation after virion entry in the early phase
of the infectious cycle
There was no signi¢cant di¡erence in virus production from
the transfected cells between WT and nef-de¢cient Lain vi-
ruses (some of the results are shown in Table 1: Relative
RT activity), and the results described above indicated that
Nef modi¢ed the viral infectivity in the early phase of infec-
tion. To clarify which step in the early phase was regulated by
the gag-pol region and Nef, we examined the virion attach-
ment/penetration with Lain viruses following a standard
method for virion entry assay [17]. MAGI cells were infected
with the same amount of Lain viruses and the amount of virus
entering the cells was estimated by p24 ELISA (Table 1: En-
try). Similar concentrations of intracellular p24 protein were
detected for both the WT and nef mutant viruses, indicating
that the impaired progression of the early infection phase by
nef mutation was not due to a block at the point of virus
entry. Analysis of proviral DNA synthesis of early (R-U5)
and late (R-gag) products was also performed 18 h after in-
fection (data not shown). It appeared that the e⁄ciency of
DNA synthesis was decreased with the nef-defective viruses
as reported previously, but we could not detect signi¢cant
e¡ects on the DNA synthesis by the substitution of the gag-
pol gene, even though the PCR analysis was performed in a
quantitative range. These results indicated the e¡ects by the
gag-pol region and Nef took place after virion entry in the
early phase of infection.
We also performed a MAGI assay in a parallel experiment
(Table 1: Infectivity). As mentioned above, the Nef e¡ect in
augmentation of viral infectivity was determined by the gag-
pol region (ApaI-Bst1107I), suggesting the possibility that one
of the functional targets of Nef is located within the gag-pol
region.
4. Discussion
The function of Nef has been reported to be dependent
upon cell type and virus strain but little is known about the
molecular mechanism of the dependence. In this report, we
described the diversity of the mutational e¡ect of the nef gene
between NL432 and LAI viruses. The aims of our study were
to obtain a clue as to the functional diversity of Nef among
HIV-1 strains and to elucidate the molecular mechanism of
Nef function in the enhancement of viral infectivity. Nef is
reported to have multi-functions in the viral life cycle, includ-
ing the enhancement of virion infectivity and the downregu-
lation of CD4 and MHC class I molecule expressions [19,20],
therefore, it is possible that several pathways are responsible
for the diversity of Nef function among HIV-1 strains. We
expected that it would be possible to limit the determinants
for the diversity by using closely related HIV-1 clones, NL432
and LAI. The 3P halves of these viruses are almost the same
but there are several substitutions in both nucleotide and ami-
no acid sequences. Even in their 5P portion, the homologies of
Gag and Pol are 93.2% and 96.5%, respectively, indicating
these HIV-1 clones are closely related.
There are many reports describing that the nef mutation
reduces viral infectivity in vitro. Although we observed the
Nefs of both NL432 and LAI could stimulate viral infectivity,
it was more marked with NL432. Although these two clones
are closely related, there were four amino acid substitutions
between these Nefs. We examined the functional diversity of
Nefs of both viruses in the enhancement of virion infectivity
by MAGI assay, and no functional di¡erence was observed
between these Nefs (Fig. 2), suggesting that the determinant(s)
was located in another part of the viral genome.
To identify the determinant(s) of the diversity, a series of
chimeric viruses were constructed and their infectivities were
analyzed. The results indicated that the ApaI-Bst1107I region
within the gag-pol gene was responsible for the diversity,
which could encode portions of Gag (NC, p6) and Pol (PR,
N-terminal portion of RT). A contribution of either PR or
RT to the diversity seemed unlikely because the nef mutation
had no e¡ect on the virion production measured with RT
activity. PR mutation is reported to have no e¡ect on virion
production but the RT activity of PR-de¢cient virions is
greatly reduced. The mechanism by which the gag region reg-
ulates the viral infectivity in connection with Nef remains
unclear. In the gag portion of the ApaI-Bst1107I region, there
are six amino acid substitutions between NL432 and LAI, and
12 amino acids are inserted in the NC protein of LAI. One
possible explanation is that the gag region acts as a target of
Nef in enhancing infectivity. As shown in Fig. 3 and Table 1,
augmentation of viral infectivity by Nef appeared to be deter-
mined by the gag-pol region, suggesting that Nef modi¢ed the
viral infectivity through interaction with the Gag-Pol precur-
sor. Although there is no report describing the direct interac-
tion between the Gag-Pol precursor and Nef, these proteins
and several cellular kinases were reported to be co-localized in
the cytoplasmic membrane [21,22], suggesting that Gag-Pol
and Nef form a complex via cellular kinases. It was reported
that Nef enhanced the phosphorylation of MA through Ser/
Thr kinase, resulting in the enhancement of viral infectivity
[23]. This report supports the idea that Gag-Pol is one of the
targets of Nef. Although the MA portion was not related to
the diversity described in this report, it is possible that other
regions within Gag-Pol also serve as a target for Nef-associ-
ated kinase. It is worth investigating the association between
Nef and the kinases that regulate the infectivity through the
phosphorylation of virion components.
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